Explore the latest in melanoma, including advances in screening, prevention, diagnosis, and management of local and metastatic disease.
This cohort study assesses the incidence of a second melanoma diagnosis after initial diagnosis among racial and ethnic minority populations.
This cohort study evaluates the association between thyroid malignant neoplasms and melanoma and other nonkeratinocyte skin cancers.
This cohort study assesses incidence of primary invasive cutaneous malignant melanoma and mortality trends in Sweden, focusing on the population younger than the mean age of melanoma onset.
This cohort study evaluates long-term survival in patients with advanced melanoma treated with immune checkpoint inhibitors outside clinical trials.
This genome-wide association study meta-analysis evaluates whether differences in risk of in situ melanoma and invasive melanoma are heritable.
This cohort study examines the association of a rule-based triage system with skin cancer risk stratification of patients and wait times.
This case series investigates the recurrence rate of melanoma in situ treated with a 5-mm margin in low-risk body sites.
A 51-year-old male with a a history of BRAF V600 E mutation-positive, superficial spreading-type cutaneous melanoma on the chest with metastasis to a sentinel lymph node had a 4-week history of redness and swelling of the right temporal bulbar conjunctiva and was referred for evaluation of a choroidal lesion in the right eye. What would you do next?
This Viewpoint discusses use of anti–PD-1 monotherapy as the primary treatment option for patients with treatment-naive metastatic melanoma staining positive for PD-L1 over dual checkpoint inhibition therapy.
This case series describes a constellation of novel adverse reactions in 3 of 9 patients with uveal melanoma receiving treatment targeting activity of the Brahma-associated factor chromatin remodeling complex.
This cohort study describes the clinical features, patient characteristics, and treatment of anti-melanoma differentiation–associated gene 5 (MDA5) dermatomyositis.
This cohort study seeks to describe the time interval between interstitial lung disease and anti–melanoma differentiation-associated gene 5 antibody-positive dermatomyositis diagnoses.
This pooled analysis of 6 clinical trials describes the safety and efficacy of different courses of immune checkpoint inhibitor treatment in a neoadjuvant setting among patients with high-risk resectable melanoma.
This Viewpoint reviews the evidence for immune checkpoint inhibitor use in the adjuvant setting, discusses the individual and societal risks, benefits, and costs associated with immune checkpoint inhibitors, and highlights the need for more targeted patient selection approaches.
This retrospective cross-sectional study illustrates national-level trends in immunohistochemistry staining for the diagnosis of melanoma in older adult patients enrolled in Medicare.
This cohort study assesses the incidence rate of second primary invasive melanoma at least 30 days after the first based on data from deidentified records of all invasive melanomas diagnosed in 2008 to 2020, obtained from the Cancer Registry of Norway.
Customize your JAMA Network experience by selecting one or more topics from the list below.